Aspirin and the risk of prostate cancer : European Journal of Cancer Prevention

Secondary Logo

Journal Logo

Advanced Search
Research papers: Prostate Cancer

Aspirin and the risk of prostate cancer

Bosetti, Cristinaa; Talamini, Renatob; Negri, Evaa; Franceschi, Silviac; Montella, Mauriziod; La Vecchia, Carloa e

Author Information

aIstituto di Ricerche Farmacologiche “Mario Negri”, Via Eritrea 62, 20157 Milan, Italy

bServizio di Epidemiologia e Biostatistica, Centro di Riferimento Oncologico, Via Pedemontana Occ.le, 33081 Aviano (Pordenone), Italy

cInfection and Cancer Epidemiology Group, International Agency for Research on Cancer, F-69372 Lyon, cédex 08, France

dServizio di Epidemiologia, Istituto Tumori “Fondazione Pascale”, Cappella dei Cangiani, 80100 Naples, Italy

eIstituto di Statistica Medica e Biometria, Università degli Studi di Milano, Via Venezian 1, 20133 Milan, Italy

Correspondence to: Cristina Bosetti, Istituto di Ricerche Farmacologiche “Mario Negri”, Via Eritrea 62, 20157 Milan, Italy

Tel: +39 02 39014526; fax: +39 02 33200231;

e-mail: [email protected]

Received 10 December 2004 Accepted 26 January 2005

European Journal of Cancer Prevention 15(1):p 43-45, February 2006. | DOI: 10.1097/01.cej.0000180665.04335.de

Abstract

Epidemiological studies have suggested that aspirin may have a protective effect against prostate cancer, but the evidence is still limited and inconsistent. The role of aspirin in prostate cancer risk was analysed in a multicentric case–control study conducted in Italy between 1991 and 2002, including 1261 incident cases of carcinoma of the prostate and 1131 hospital controls. A total of 115 (9.1%) cases versus 90 (8.0%) controls reported regular aspirin use. The multivariate odds ratio (OR) for regular aspirin users was 1.10 (95% confidence interval (95% CI) 0.81–1.50). No relation was found with duration of use (OR=1.03 for <5 years, and 1.17 for ≥5 years) and time since first use (OR=1.03 for <10 years, and 1.35 for ≥10 years). These findings do not support a protective role of regular aspirin use on prostate cancer risk.

© 2006 Lippincott Williams & Wilkins, Inc.

Full Text Access for Subscribers:

Not a Subscriber?

Buy
Request Permissions

You can read the full text of this article if you:

Access through Ovid